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Cisplatin is a commonly used platinum anti-cancer drug. Regrettably cisp-
latin has dose-limiting ototoxic side effects, e.g. the drug can induce an ir-
reversible hearing loss. The ototoxic mechanisms of cisplatin have not been 
elucidated in the human ear and no clinically useful oto-protectors are yet 
available. Cisplatin is a necessary part of many treatment regimes. Its bene-
ficial therapeutic effects might be reduced if cisplatin was excluded from the 
treatment in order to protect the hearing function. In this work the ototoxic 
effects of cisplatin are studied with the aim to better understand the mecha-
nisms behind the irreversible hearing loss induced by this drug. Oxaliplatin is 
a second generation platinum-derivative anti-cancer drug, free from ototoxic 
side effects in clinical practice. The effects of oxaliplatin on the inner ear have 
been studied in this work and the results are compared with cisplatin treat-
ment. The two drugs differ regarding both anti-cancer effects and side effects, 
which could be attributed to differences in pharmacokinetic factors, cellular 
uptake and apoptotic mechanisms. The thioredoxin redox system with the 
enzyme thioredoxin reductase (TrxR) was studied in cochleae due to a sug-
gested DNA-independent apoptotic mechanism of the hair cells. The cochlear 
pharmacokinetics of cisplatin was assessed and the transport protein organic 
cation transporter 2 (OCT2) was studied in relation to the ototoxic effect of 
cisplatin.
 
Material and methods 
Cultured human colon carcinoma cells and cell cultures of rat organ of Corti 
were used for apoptosis studies in vitro following exposure to cisplatin and 
oxaliplatin. Cisplatin and oxaliplatin were administered i.v. to guinea pigs, 
followed by in vivo sampling of blood, cerebrospinal fluid (CSF) and scala 
tympani (ST) perilymph. Liquid chromatography with post-column derivati-
zation was used to determine the concentration of parent drug in the samples. 
Electrophysiological hearing thresholds and the loss of hair cells were as-
sessed to evaluate their ototoxic effects. Phenformin, a potential blocker of 
OCT2 was administered and the ototoxic side effect of cisplatin was evalua-
ted. For immunohistochemical studies, cochlea from rat, guinea pig and pig 
were used, where TrxR and OCT2 were evaluated in the cochlea. TrxR-assays 
were used to measure the TrxR activity in cochlear tissue, both in vivo and in 
vitro.
7Results 
The results from the in vitro studies showed that addition of either cisplatin 
or oxaliplatin to the culture medium in organ of Corti cell cultures caused a 
similar amount of outer hair cell loss and inhibition of TrxR activity. Cisplatin 
exposure to cultured human colon carcinoma cells also reduced the activity 
of TrxR. The results from the in vivo studies showed that a considerable con-
centration of cisplatin was present in ST perilymph as compared with weak 
concentrations of oxaliplatin after high dose oxaliplatin i.v. Ten minutes after 
cisplatin administration, its concentration in ST perilymph was 4-fold higher 
in the basal turn of the cochlea as compared to the apex. Cisplatin could be 
analysed in ST perilymph for up to 120 min. Phenformin i.v. did not reduce 
the ototoxic side-effect of cisplatin. Positive immunoreactivity to TrxR was 
evident in both hair cells and spiral ganglion cells. Futhermore, OCT2 was 
expressed in the supporting cells of organ of Corti and in the spiral ganglion 
cells. 
Conclusion 
The transport of cisplatin to the vulnerable cells of hearing seems to be of ma-
jor importance for the ototoxic effects. An early high concentration of cispla-
tin in the base of the cochlea and delayed elimination of cisplatin from ST pe-
rilymph may be related to the cisplatin-induced loss of outer hair cells in the 
basal turn of the cochlea. Cisplatin and oxaliplatin both cause similar ototoxic 
effects when the organ of Corti is directly exposed in vitro. The thioredoxin 
redox system with the TrxR enzyme may well play a critical role in cisplatin-
induced ototoxicity. The presence of OCT2 in the supporting cells indicates 
that this transport protein is primarily not involved in the uptake of cisplatin 
from the systemic circulation but rather from the deeper compartments of 
the cochlea. The knowledge elicited in this work will hopefully suggest ob-
jectives for further studies in order to develop oto-protective treatments to 
preserve the hearing of cisplatin treated patients.
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1.1 Ototoxicity      
Ototoxicity in its widest sense comprises several drug-induced toxic effects 
on hearing and balance. Ototoxicity can be either irreversible or reversible. 
Loop diuretics such as furosemide and the anti-malaria drug quinine can in-
duce a reversible ototoxic effect in the cochlea and/or the vestibular organ. 
Aminoglycoside antibiotics and the anti-cancer drug cisplatin can cause irre-
versible ototoxic effects. In the clinical setting, cisplatin-induced hearing loss 
is dose-dependent, with an obvious individual variability in susceptibility [1]. 
In Swedish patients cisplatin is the most common cause of drug-induced hea-
ring loss which is often accompanied by tinnitus [2-4]. The cellular mecha-
nisms underlying the ototoxic effects are complex and not fully elucidated. 
Although much experimental research has been performed, no clinical oto-
protector is yet available that protects the hearing without counteracting the 
antineoplastic effects of cisplatin. In this work the ototoxic effects of cisplatin 
were studied with the intention to better understand the mechanisms causing 
the irreversible hearing loss induced by the drug.
1.2 Cancer 
Cancer is an uncontrolled proliferation of a cell population. Treatment of can-
cer often utilizes multiple modalities such as surgery, radiation and chemoth-
erapy, alone or in combinations. 
1.3 Apoptosis
Apart from apoptosis of cells in healthy physiology, a pathological form of 
apoptosis is significant in diseases such as Parkinson’s disease and ALS. Apo-
ptosis must be distinguished from necrosis which is described to be a trau-
matic cell death that can be secondary to mechanical trauma, ischaemia, or 
thermal injury. This causes cells to swell, releasing cytoplasm and induce 
an inflammatory response. Apoptosis is a complex energy dependent pro-
cess of programmed cell death [5]. First the cell forms cytoplasmic blebs and 
apoptotic bodies before it starts to shrink, resulting in condensed cytoplasm 
and fragmented nuclei. The cell membrane is often intact and there is no in-
flammation. Apoptosis follows two main ways pathways: the extrinsic or the 
intrinsic. The extrinsic signalling pathway initiates apoptosis via transmem-
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brane death receptors that are members of the tumour necrosis factor receptor 
gene superfamily. Death receptors mediate apoptosis via an activation of the 
effector caspase 3. The intrinsic pathway is initiated through the cell mito-
chondria, inducing caspase 3 activation. Calcium is also important for the 
apoptotic pathways [6]. 
1.4 Chemotherapy 
Chemotherapeutic drugs induces apoptosis primary in cancer cells having a 
rapid growth rate. The use of chemotherapy in reality requires a balance bet-
ween killing cancer cells while ensuring a sufficient survival of healthy cells, 
in order to minimize side effects. Consequently anti-cancer drugs have both 
dose dependent and dose limiting side effects. The cytotoxic effects are medi-
ated by various mechanisms. The drug can have a direct deoxyribonucleic 
acid (DNA) binding capacity, or it can inhibit the DNA-independent cellular 
machinery that affects division of cells. Anti-cancer drugs are divided into 
different categories, depending on differences in cytotoxic effect. Anti-meta-
bolites such as methotrexate block enzymes that are necessary for DNA syn-
thesis. Alkylating agents such as cyclophosphamide and the platinum-based 
drug, as cisplatin are cell-cycle-independent and their major anti-neoplastic 
effects are mediated by formation of DNA intrastrand cross-links.
Cisplatin has been used in cancer treatment for more than 40 years. It is of-
ten combined with other anti-cancer drugs. New platinum-based anti-cancer 
drugs have been developed with the purpose of limiting the side effects and 
to improve the anti-cancer effect of cisplatin. Several drugs have entered 
clinical trials but only carboplatin and oxaliplatin have been approved world-
wide, but cisplatin is still the most potent of these drugs [7]. Carboplatin was 
introduced in the late 1980s and it is currently used to treat ovarian cancer and 
small-cell lung cancer [8]. The major dose-limiting side effect of carboplatin 
is myelosuppression [9]. Ototoxic and nephrotoxic side effects are mentioned 
as common, but are rarely seen in clinic. Oxaliplatin was studied in this work 
due to the fact that it does not affect the hearing and our experimental results 
are therefore of interest when comparing this drug with cisplatin. 
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1.5 Cisplatin 
Cisplatin (cis-diammine-dichloro-platinum, with the chemical formula 
H6Cl2N2Pt, Platinol
®) is a small, uncharged, water-soluble molecule with a 
molecular weight of 300 g/mol. The central platinum core is surrounded by 
two stable amine groups and two reactive chloride groups (Fig. 1). The plati-
num-based drug cisplatin was first discovered by the American chemist Bar-
nett Rosenberg (1926 – 2009). In 1965 Rosenberg and his colleague showed 
that bacterial cell division could be inhibited by cisplatin [10]. Four years la-
ter they described the cytotoxic effect of cisplatin [11]. The first clinical study 
of cisplatin was presented in 1972 [12] and in 1978 cisplatin was approved 
for the treatment of testicular and ovarian cancers in the USA. Today cispla-
tin is used in the treatment of testicular cancer [13], ovarian cancer, bladder 
cancer, lung cancer and head and neck cancer [14] and against paediatric ma-
lignancies [15] such as medulloblastoma [16], osteosarcoma [17] and neuro-
blastoma [18]. The use of cisplatin against testicular cancer has substantially 
improved the survival rate. 
In clinical use, cisplatin is usually administrated i.v. in a high-dose or a 
low-dose regimen at a dose of 40-75 mg/m² administer in repeated cycles. 
Cisplatin can also be administrated intraperitoneally [19]. About-one third 
of the patients treated with a high dose regimen (doses exceeding 60 mg/
m²) develop a hearing loss [1, 3, 20]. When severe hearing loss occurs 
during cisplatin treatment the drug is often excluded and the carcinogenic 
effects of treatment may then be reduced [2, 4]. Besides its ototoxic side 
effect, cisplatin has nephrotoxic side effects. The renal damage caused by 
cisplatin is often successfully alleviated by pre-treatment with hydration and 
forced diuresis [21]. Cisplatin can also induce gastrointestinally toxic and 
cause neurological side effects giving rise to a distal sensory neuropathy 
[22, 23].  
Fig. 1. The molecular formulae of cisplatin and oxaliplatin.
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1.6 Oxaliplatin 
Oxaliplatin (oxalate (1R,2R-cyclohexandiamine) platina (II), with the mole-
cular formula C8H14N2O4Pt, Eloxatin
®) is a small uncharged molecule with a 
molecular weight of 397 g/mol, having a central platinum core and reactive 
ligands (Fig. 1). In oxaliplatin the two chloride ligands have been replaced by 
a single oxalate ligand, and is thus less resistant than cisplatin as the diffe-
rent adducts formed with DNA [24] prevent binding of DNA repair proteins. 
No ototoxic or nephrotoxic side effects have been reported [25]. The oxalate 
ligand also greatly alleviates the severity of the side effects of the drug com-
pared with cisplatin [24]. Oxaliplatin was first used in the USA in 2002 [26]. 
It is prescribed to treat metastatic colorectal cancer [27], ovarian cancer [28], 
metastatic breast cancer [29], pancreatic cancer [30] and esophagogastric can-
cer [31].  In clinical practice oxaliplatin is i.v. administered in repeated cycles 
at doses of 85-130 mg/kg [32]. Oxaliplatin can also be administered locally as 
an intraperitoneal chemotherapy [33, 34]. Neurotoxicity is the dose-limiting 
effect of oxaliplatin [35-37].  
1.7 Cytotoxic effects of cisplatin and oxaliplatin
Due to different toxic profiles both in targeting cancer and side effects, there 
might be a variation in the specific drug transport and/or apoptotic mecha-
nisms for cisplatin and oxaliplatin. Platinum based drugs probably enter cells 
mainly through passive diffusion but active transport mechanisms have also 
been proposed [38-43]. Cisplatin [44, 45] and oxaliplatin [40, 46-48] both 
form cross-links between the DNA strands and thereby inhibit cell transcrip-
tion and replication. At equimolar doses, oxaliplatin produces fewer DNA 
adducts than to cisplatin but is equally potent [49]. This could be explained 
by difference in platinum-DNA adducts and differences in the DNA repair 
mechanism [46, 50]. There are also DNA-independent mechanism of apopto-
sis [6] involved which has been demonstrated to be caused in enucleated cells 
by inducing endoplasmic reticulum (ER) stress and a caspase activation [51, 
52]. It has been shown that cisplatin interacts with RNA, mitochondrial DNA 
[53-55] and proteins involved in the antioxidant systems, energy production 
and with cell signalling peptides [56-58]. Today it is known that cisplatin and 
oxaliplatin increases the cytoplasmic levels of toxic free radicals, i.e. reactive 
oxygen species (ROS), in the apoptotic process of the cell [34, 59, 60].
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1.8 Redox system
Oxidation reactions are necessary for cellular life and cells have several oxi-
dative substances and corresponding redox systems. The oxidation process 
produces ROS that can initiate reactions, leading to cell apoptosis. Oxidative 
stress is potentially dangerous and is involved in the development of many di-
seases including several forms of cancer [61]. A number of antioxidants such 
as glutathione and vitamins A, C and E are used for the treatment or preven-
tion of diseases. The glutathione (GSH) and the thioredoxin (Trx) systems are 
the two major redox systems in cells [62]. 
The Trx-system contains the 12 kDa protein thioredoxin (Trx) and the en-
zyme thioredoxin reductase (TrxR). Trx has 2 cystine groups that can cycle 
between an active reduced dithiol form and an oxidized disulphide form. The 
reduced form of thioredoxin has strong anti-oxidative properties [63]. After 
the Trx protein is oxidized, the enzyme TrxR regenerate the oxidized Trx to 
an active, reduced form [64]. The Trx redox system has been shown to be 
involved in the cytotoxic effect of cisplatin and oxaliplatin [65-67]. Cispla-
tin and oxaliplatin are known to bind to the selenocysteine-containing active 
site on TrxR, a site that is important for the reduction capacity of TrxR. The 
activity of the enzyme is thereby reduced [65, 66]. The Trx redox system is 
thereby inhibited and the level of ROS is increased which may be deleterious 
for cells [67]. 
Due to the fact that hair cells are non-replication, a DNA-independent mecha-
nisms of apoptosis are supposed to be involved and it is shown that cisplatin 
induces an oxidative stress pathway, i.e. reducing anti-oxidation enzymes in 
the cochlea [68, 69]. The concentration of ROS is thereby increased. This 
induces an oxidative stress that activates apoptotic mechanisms in the inner 
ear. The exact mechanisms are far from fully clarified. Intracellular antiox-
idants related to the GSH system are previous studied in relation to cisplatin 
induced apoptosis of the hair cells [56, 68, 70, 71]. In this work, the Trx redox 
system is studied in relation to the cytotoxic effect of cisplatin and oxalipla-
tin and for the involvement in cisplatin-induced ototoxicity. TrxR is studied 
immunohistohemically in the rat and guinea pig cochlea. After cisplatin and 
oxaliplatin treatment the activity of TrxR are measured both in vitro and in 
vivo i.e. in cultured colon carcinoma cells, in rat organ of Corti cell cultures 
and in cochlear tissue from guinea pigs.
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1.9 Pharmacokinetics 
The pharmacokinetics of a drug is studied by analysing the drug concen-
trations at different time points in different compartments, which can be 
summarized as what is happening to the drug in the body. In this work the 
pharmacokinetic profiles of cisplatin and oxaliplatin were assessed in blood, 
cerebrospinal fluid (CSF) and in the most voluminous cochlear fluid, the pe-
rilymph. “The area under the concentration time curve” (AUC), peak concen-
tration and the elimination half-time of the drug were measured and calcula-
ted. In blood, cisplatin and oxaliplatin bind to albumin, whereby the drugs 
lose most of its cytotoxic properties [72, 73]. The unbound fraction of the pa-
rent drug represents the “active” part of the drug [72, 74]. Either cisplatin or 
oxaliplatin are enzymatic metabolized and both drugs are excreted via renal 
filtration. In this work all pharmacokinetic results derive from the concentra-
tion of the unbound, active part of cisplatin and oxaliplatin, respectively [75, 
76]. In previous studies it has been shown that the blood elimination half-life 
of cisplatin was approx. 23 min after patients had undergone a 1-hour infu-
sion of cisplatin 100 mg/m² [77, 78] and for oxaliplatin, 14 min when patients 
received 85 mg/m² oxaliplatin in 2-hour i.v. infusion [73, 75]. The pharma-
cokinetic profile of cisplatin in blood is of important for drug transport to the 
inner ear, as is shown in this work [79, 80]. 
1.10 The cochlea
Anatomy 
Fig. 2 shows the anatomy of the cochlea. The human cochlea consists of two 
and a half turns (approx. 31 mm from the base to the apex) compared to three 
and a half turns in the guinea pig (approx.19 mm from base to apex) [81, 82]. 
The bony cochlea harbours the membranous labyrinth with three fluid-filled 
compartments i.e. scales; scala media (SM), scala tympani (ST) and scala 
vestibuli (SV). Reissner’s membrane separates SM from SV and the basilar 
membrane separates SM from ST. Helicotrema is a passage in the most apical 
part of the cochlea, connecting ST with SV. There are two openings in the 
cochlear bone i.e. the oval and the round window. The stapes foot-plate from 
the middle ear bone is attached to the oval window that is heading to SV. The 
round window membrane is connected to ST. The modiolus is the central 
bony part of the cochlea containing the spiral ganglion cells (SGCs) and the 
peripheral neurons of the cochlear nerve located in Rosentahl´s canal. The or-
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gan of Corti, with the inner hair cells (IHCs) and outer hair cells (OHCs) and 
surrounding supporting cells (SC) are situated on the surface of the basilar 
membrane. 
Fig. 2.  A cross-section of the cochlea with its basal and apical parts. The capillary 
tubes show from where scala tympani perilymph was aspirated from both 
the cochlear base and apex. (Gray´s Anatomy, Wikimedia Commons)
Cochlear fluids 
There are two different fluids within the cochlea. Endolymph has a high con-
centration of potassium and a low concentration of sodium, very much like 
the intracellular fluid. SM is filled with endolymph [83, 84]. Endolymph is 
believed to derive from  stria vascularis; it regulates the endolymphatic poten-
tial [85]. Perilymph on the other hand has a high concentration of sodium and 
a low concentration of potassium. It is very much like the extracellular fluid. 
ST and SV are filled with perilymph i.e. ST perilymph and SV perilymph. 
Perilymph is believed to be produced “locally” and does not derive from 
CSF as supposed earlier. ST perilymph has an extremely slowly turnover rate 
and the circulation route of the fluid is from base to apex of the cochlea [86]. 
Cortilymph fluid was previus described to be the fluid localized around the 
basal parts of the hair cells, but today it is known that it is ST peilymph that 
is surrounding the OHCs and the tunnel of Corti [87]. The ionic composition 
of endolymph and perilymph does not differ significantly between humans 
and other species [82, 88-91]. The total volume of ST perilymph in a guinea 
pig is calculated to be around 4.7 µL and in a human cochlea, 29.2 µL [90, 
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91]. ST perilymph communicates with CSF via the cochlear aqueduct that is 
a passage situated very close to the round window in the base of the cochlea. 
This passage is very narrow and is known to be open in animals, but its morp-
hology  in the human cochlea is uncertain [92]. In this work, ST perilymph 
was sampled from the basal turn and from the apex of the cochlea, shown in 
Fig. 2. 
Organ of Corti
Fig. 3 shows the organ of Corti with the IHCs, OHCs and the surrounding 
SCs. The pear-shaped IHCs are the primary sensory receptors that convert 
mechanical energy, i.e. movements in the basilar membrane, to nerve impul-
ses with an afferent nerve transport to the central nerve system. The cylin-
drical OHCs are connected mainly to efferent neurons via the olivocochlear 
pathway, an efferent feedback system, which modulates hearing sensitivity 
[93-95]. The OHCs are also known as the cochlear amplifier [96]. They acts 
as “motors” that compensate for energy loss in the cochlea along “the tra-
velling wave” [93, 97]. The cochlea has one row of IHCs and three rows of 
OHCs. The human cochlea has about 12,000 OHCs and 3,500 IHCs [98]; the 
guinea pig has approx. 6,500 OHCs and 1,900 IHCs [99]. 
Stereocilia are located on the apical surface (cuticular plate) of the hair cells. 
The tallest tips of the OHCs stereocilia are embedded in the overlying tecto-
rial membrane, whereas the tips of the stereocilia on the IHCs are not. The 
human OHC has about 50-150 stereocilia, localized in three of four rows with 
a V-shaped configuration. The human IHC has about 60 stereocilia situated in 
more flat U shape, and they are shorter in the base of the cochlea. Stereocilia 
have cross-linked actin filaments from the tip to the base of the stereocilia 
[100]. The basal parts of the OHCs are connected to ST perilymph [101] 
while their most apical parts with the stereocilia are situated in the endolymph 
[100, 102].
The SCs are also terminally differentiated cells. They are not only important 
the bolstering of the hair cells, they also have an important function in the re-
cycling of potassium that is released from the hair cells, thereby maintaining 
the action potential [85, 103]. Deiters´ cells connect the OHCs to the basal 
membrane [104, 105]. The inner sulcus cells [85, 106] are situated medially. 
The inner and outer pillar cells form the tunnel of Corti. Hensen´s cells and 




The basilar membrane forms the floor of SM. It consists of connective tis-
sue and its anatomical structure is of a paramount importance for separating 
sound frequencies. It is wider in cochlear apex, generating low frequencies 
and in the base of the cochlea where it is more narrow and stiffer, generating 
high frequencies of sound [108]. 
Spiral ganglion cells 
Spiral ganglion cells (SGC) are the cell bodies of the neurons in the cochlear 
nerve. The SGCs are located in the modiolus of the cochlea. The carry a 
peripheral neuron that is leading towards the organ of Corti and a process 
connected with the cochlear nucleus. There are two different types of SGC, 
types I and II. The myelinated type I cells (95%) are relatively large cells and 
have a pronounced nucleus, many mitochondria, Golgi apparatus, ribosomes, 
neurofilaments and an endoplasmic reticulum [95]. The peripheral neuron of 
type I cells is afferently attached to the IHCs [109]. The unmyelinated type 
II cells (5%) are rather small and the peripheral neuron is mainly efferently 
connected with the OHCs [95, 107].
Stria vascularis 
Stria vascularis is the vascularized epithelium in the lateral wall of the cochlea. 
It has three layers of cells i.e. the marginal cells leading toward the endo-
Fig. 3. Organ of Corti (Gray´s Anatomy, Wikimedia Commons)
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lymph in SM, the intermediate cells, and the basal cells. By active processes 
stria vascularis maintains a high concentration of potassium in SM thereby 
giving a positive potential of +80 mV [85]. 
Spiral ligament
Stria vascularis and the more laterally situated spiral ligament are known as 
the lateral wall of the cochlea. The spiral ligament supports stria vascularis 
and consists mostly of fibroblast but also has a vascular epithelium and seems 
to be involved in the re-cycling process of potassium [106, 110].
1.11 The ear and hearing 
The sense of hearing is an extremely complex process. Sound waves pass th-
rough the auditory canal where upon the tympanic membrane starts to vibra-
te. The middle ear with the ossicular chain i.e. the malleus, incus and stapes, 
transfer mechanical energy via movements in the oval window. This energy is 
further converted by the perilymph, creating a wave on the basilar membrane 
that travels from the base toward the cochlear apex i.e. the travelling wave. 
Movements in the basilar membrane deflect the stereocilia in the covering 
tectorial membrane.
The IHCs converts mechanical energy into nerve impulses in the central ner-
vous system. This is due to opening of specific mechanically gated ion chan-
nels when the stereocila are deflected in the direction of the tallest stereocilia. 
This induces an influx of and potassium from the endolymph enters the IHCs 
which are then depolarized. Calcium channels open resulting in release of 
neurotransmitters (i.e. glutamate), generating nerve impulses in the attached 
afferent fibres in the base of IHC. Nerve impulses are transmitted via the af-
ferent fibres of the type I SGCs and further via the cochlear nerve (the cranial 
nerve no.VIII, vestibulocochlear nerve) to the cochlear nucleus in the brain 
stem and then processed to the auditory cortex in the temporal lobe. The au-
ditory sensory epithelium is organized along  specific frequencies distributed 
along a tonotopic axis along the cochlea to a tonotopic map in the auditory 
cortex [111]. When sound waves decreases, the sterereocilia are defleced 
toward the shortest stereocilia, the ion channels close. The function of the 
OHCs as a cochlear amplifier are of a paramount importance for the afferent 
nerve transport of the IHCs [93-96]. Disruption of the OHCs causes hearing 
loss at the associated frequencies. 
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1.12 Ototoxicity of cisplatin 
Damage to hair cells that have a very low DNA-turnover leads to perma-
nent hearing loss, i.e. an irreversible sensorineural hearing loss. Cisplatin 
treatment affects mostly the OHCs in the basal part of the cochlea, inducing 
hearing loss in high-frequencies. Hearing loss in the speech frequencies can 
also be impaired after high dose cisplatin treatment. In humans, the hearing 
loss becomes evident after some days after cisplatin treatment [105, 112]. 
Fig. 4 show a tone audiogram from a child treated with cisplatin. 
In animal studies the ototoxic effect is often determined with auditory brain-
stem response (ABR) and, histologically, loss of hair cells is calculated post 
mortem. When guinea pigs are given an ototoxic dose of cisplatin, a sig-
nificant reduction in electrophysiological hearing thresholds, mostly at high 
frequencies, becomes evident after 96 hours. This is caused mainly by a da-
maged OHCs and SC in the base of the cochlea [105, 113-115]. Some studies 
have also reported lesions to the IHCs, SGCs [116-118] and stria vascularis 
[105, 113, 119, 120]. After high-dose treatment with cisplatin the morpholo-
gical damage progresses towards the apical part of the cochlea [105, 114, 115] 
The OHCs in the first row are more severely affected than the second and 
third rows [105, 115]. In this work the ototoxic effect of cisplatin was evalua-
ted in experimental animals by measuring the electrophysiological hearing 
thresholds with ABR and morphological studies were performed to calculate 
loss of the hair cells. 
Fig. 4.  A tone audiogram from a 4 years old child treated with cisplatin, 
showing a profound bilateral sensorineural hearing loss at the 
high frequencies of hearing. (Patient met at clinic.)
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The individual variability in susceptibility of the ototoxic side effect of cisp-
latin is seen both in clinic and in animal studies [1, 121, 122]. Elderly patients 
[1, 123] and children [124] seem to be more susceptible to the ototoxic effect 
of cisplatin. When cisplatin is given as single high [1] or a high cumulative 
dose [1, 124] the ototoxic effect is more pronounced. Ekborn and co-workers 
(2000) showed that the severity of hearing loss due to cisplatin was not rela-
ted to the drug infusion rate [125]. 
1.13 Nephrotoxicity of cisplatin
Cisplatin affects the endothelial cells in proximal tubules in the kidney [126]. 
The proximal tubule is responsible for active reabsorption of sodium chloride. 
Renal failure with reduced renal clearance produces elevated concentrations 
of S-creatinine and S-urea [127]. Renal damage due to cisplatin treatment 
can be alleviated by hydration and a forced diuresis [128]. Cisplatin-induced 
apoptosis of the renal cells is associated with oxidative stress pathways. Both 
GSH redox system [57] and Trx redox system appears to be involved in the 
nephrotoxic effect of cisplatin [129, 130].
1.14 Monohydrated complex of cisplatin
A major biotransformation product of cisplatin is called the monohydrated 
complex (MHC). MHC is formed when cisplatin is hydrolysed in water, the-
reby losing a chloride ion and gaining a water molecule [76] (Fig. 5). Envi-
ronmental factors such as low chloride concentration and low pH favour the 
formation of MHC [74, 131]. MHC appears to be more toxic than to cisplatin 
[79, 132]. The positively charged MHC has a stronger affinity for the negati-
vely charged DNA and this could be one explanation for the increased toxici-
ty of MHC compared to cisplatin [45]. It is known that MHC generates ROS 
and the oxidative stress pathway might be involved in the nephrotoxic side 
effect of cisplatin [133, 134]. The relationship of MCH to the ototoxic side 
effect of cisplatin has not been fully evaluated, but MHC in ST perilymph was 
analyzed in this work
Fig. 5. The monohydrated complex (MHC) of cisplatin. Cisplatin is hydro-
lyzed in water; loses a chloride ion and gains a water molecule. 
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1.15 Inner ear pharmacokinetics of cisplatin 
The knowledge of the distribution of and elimination of cisplatin from the 
inner ear is limited. For pharmacokinetic studies, reliable in vivo models are 
needed as this type of knowledge cannot be obtained in human beings. In ani-
mal studies cisplatin can be  administered systemically as a i.p. or i.v. infusion 
but it can also be instilled directly to the middle ear [135] or directly into the 
inner ear [136, 137]. Laurell and co-workers (1995), showed that a paramount 
concentration of cisplatin could be measured in ST perilymph after i.v admi-
nistration of high-dose cisplatin [80]. It is know that the longitudinal flow 
of perilymph is a very slow from the base to the apex of the cochlea [138] 
and cisplatin seems to be transported by longitudinal diffusion. There is also 
diffusion between different compartments of the cochlea, followed by a eli-
mination through the vascularized tissue [139, 140]. It is also known that the 
concentration of cisplatin is greater in perilymph compared to the endolymph, 
following systemic administration [141]. In this work, the pharmacokinetic 
distributions of cisplatin were studied in the ear after i.v. bolus dose of cisp-
latin to guinea pigs. The concentration of cisplatin in blood and its transport 
to the inner ear is of basic is importance for understanding of the inner ear 
pharmacokinetics of cisplatin, as was also found in the present work.
1.16 Inner ear barriers 
Cisplatin was initially thought to be transported to different compartments in 
the body by passive diffusion [142]. It is not known how cisplatin enters the 
perilymphatic and endolymphatic compartments in the inner ear, but passive 
diffusion and an active transport  using specific transport proteins have ear-
lier been discussed [39, 143]. Two barrier systems are described, partly with 
the function of protecting the inner ear from toxic substances: the intrastrial 
fluid–blood barrier and the blood–perilymph barrier. The vascular supply to 
the cochlea is of a paramount importance for these two barriers. 
The main arterial vessel to the cochlea derivates from the basilar artery, fol-
lowed by the anterior inferior cerebellar artery, which gives off a branch to 
the labyrinthine artery (inner ear artery), a terminal artery without collaterals. 
The common cochlear artery ends up in the spiral modiolar artery. The spiral 
modular artery give branches of radiating arterioles. One branch terminate 
in capillaries of stria vascularis and the spiral ligament [144, 145]. Another 
branch terminate in capillaries in spiral lamina and in the basal membrane in 
location under the tunnel of Corti.
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The intrastrial fluid–blood barrier
The concept of a blood–labyrinth barrier has been used previously [146, 147], 
but the current definition of an intrastrial fluid–blood barrier is more common 
thanks to better knowledge of the structure and function of the barrier [148]. 
The capillary endothelium connected with tight junctions in stria vascula-
ris and spiral ligament is representative of the intrastrial fluid–blood barrier 
[86, 140, 146, 147, 149-155]. Cochlear pericytes and perivascular resistant 
macrophage-type melanocytes are recently identified cells in the intrastrial 
fluid–blood barrier [148]. 
The blood–perilymph barrier 
 
The vessels in the spiral lamina, and capillaries of the basal membrane are 
vessels that support the blood–perilymph barrier, but its structure is not pre-
cisely known [156].
1.17 Blood–CSF barrier 
The choroid plexus in the ventricular system of the brain produces CSF and 
also acts as a barrier preventing toxic substances from passing into the CSF, 
i.e. a blood–CSF barrier [157]. The blood–CSF barrier is separated from the 
blood–brain barrier [158, 159]. CSF is produced when plasma is filtered from 
the blood through the epithelial cells into the choroid plexus which is sealed 
with tight junctions to prevent toxic substances from passing into CSF. Cisp-
latin can be measured in CSF [80, 160, 161] which means that the drug is able 
to penetrate the blood–CSF barrier in vivo. It has also been shown that cis-
platin can be measured in human CSF [161-164]. The hydrophilic molecule 
cisplatin has a restricted access to the brain and is not primarily used for ma-
lignancy in the central nervous system. In combination with other anti-cancer 
drugs cisplatin is used to treat paediatric medulloblastoma [165].
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1.18 Transport proteins within the cochlea
Various active mechanisms have been discussed regarding the transport of 
cisplatin to cells vulnerable for hearing loss. Whether or not there is a dif-
ferent transport mechanism involved in the influx of cisplatin from blood 
to the inner ear fluids, or for the uptake of cisplatin to OHCs, remains to be 
ascertained. One hypothesis in this work is that there is a drug-specific trans-
port mechanism for cisplatin to the inner ear. The membrane protein organic 
cation transporter 2 (OCT2), and the copper transporter 1 (Ctrl) are the two 
most studied transport proteins regarding cisplatin toxicity. Various isoforms 
of OCTs have specific species- and tissue-distribution patterns [166, 167]. It 
was earlier demonstrated that both Ctr1 [38, 168] and OCT2 [39, 168] are ac-
tually involved in cisplatin-induced ototoxicity. In this work OCT2 has been 
studied regarding the ototoxic side effect of cisplatin [169]. 
1.19 Oto-protection
Although other researchers have attempted to contribute knowledge regar-
ding protection of hearing in addition to cisplatin treatment, no oto-protective 
measures have actually succeeded in clinical practice. Knowing that cisplatin 
does increase the level of ROS in hair cells, several antioxidant therapies have 
been studied to offer oto-protection [170-172]. A number of sulphur-contain-
ing compounds, such as N-acetyl-cysteine, sodium thiosulphate [173] and 
D-methionine [174], are antioxidants with a high affinity to platinum species. 
Unfortunately these drugs also counteract the anti-tumour effects when they 
administered systemically [121]. Local application of antioxidants to the ear 
is therefor to be preferred [175-177] [177]. Another way for oto-protection 
is to block the uptake of cisplatin in the inner ear so as to prevent high cisp-
latin concentrations from reaching vulnerable auditory cells. When transport 
inhibitors and competitors such as copper sulphate [38] and cimetidine [39, 
178, 179] are administrated i.v. they interact with active transport of cisplatin 
[180]. In this work, a potential blocker of OCT2 (phenformin) was studied as 
regards to the ototoxic sides effect of cisplatin. 
30
2. AIMS 
The overriding aim of the research presented in this thesis was cisplatin-in-
duced ototoxicity and how it is affected by the pharmacokinetics of the drug, 
in particular as related to transport mechanism to and potentially protective 




1. To study the cochlear pharmacokinetics of cisplatin and oxaliplatin, 
and ascertain if the pharmacokinetic distribution of the parent drug can 
explain the ototoxic side effects of cisplatin. 
2. Study DNA-independent apoptotic mechanisms and suggested involve-
ment of the Trx redox system in cultured colon carcinoma cells following 
treatment with cisplatin or oxaliplatin. 
3. Evaluate if TrxR could be identified immunohistochemically in the 
cochlea.
Paper II
1. To study the distribution of cisplatin in ST perilymph, blood, and CSF 
after i.v. infusion.
2. To compare the concentrations of cisplatin in the base and apex of the 
cochlea.
3. Establish how long cisplatin could be measured in ST perilymph.
Paper III
1. To study the loss of hair cells following direct administration of cisplatin 
or oxaliplatin to cultured organ of Corti. 
2. Study the Trx redox system in cochlear tissue after exposure to oxaliplatin 
or cisplatin, both in vitro in and in vivo.
Paper IV
1. To identify the cellular distribution of OCT2 in the cochlea in 
various species, using immunohistochemical methods. 
2. Investigate if phenformin, a potential OCT2-blocker, could prevent 
cisplatin-induced ototoxicity in vivo.
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3. MATERIAL AND METHODS 
Experimental design, papers I-IV
Paper I 
In vitro studies: Cultured colon carcinoma cells were used to study DNA-
independent mechanisms of apoptosis and the activity of TrxR was assessed 
after treatment with cisplatin or oxaliplatin. 
In vivo studies: Guinea pigs were given a high dose of i.v. oxaliplatin (16.6 
mg/kg) or a low non-ototoxic dose of i.v. cisplatin (5 mg/kg). The pharmaco-
kinetic distribution of the drugs was determined in blood, CSF, and ST peri-
lymph up to 90 min after the parent drug was administered. Electrophysiolo-
gical hearing thresholds were determined, using ABR, hair cells were counted 
and the platinum content was determined in cochlear tissue. 
Morphological studies: The expression of TrxR was evaluated 
immunohistologically in guinea pig cochlea.
Paper II
In vivo studies: The pharmacokinetics of cisplatin in guinea pig cochlea was 
evaluated after i.v. administration of an ototoxic dose of cisplatin (8 mg/kg). 
Blood, CSF and ST perilymph were aspirated 10-180 min after drug admi-
nistration and the concentration of cisplatin was assessed. ST perilymph was 
aspirated from both the cochlear base and apex during the first 30 min after 
drug administration.
Paper III 
In vitro studies: The apoptotic effects on the hair cells and the activity of TrxR 
were evaluated in organ of Corti cell cultures exposed to either an equimolar 
dose of cisplatin or oxaliplatin. 
In vivo studies: An ototoxic dose of cisplatin (8 mg/kg) or an equimo-
lar dose of oxaliplatin (10.6 mg/kg) was administered i.v. to guinea pigs. 
After 24 hours, inner ear tissues were analysed for TrxR activity. 
Paper IV
Morphological studies: The localization of OCT2 was characterized immuno-
histochemically in the cochlea of three different animal species.
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In vivo studies: Phenformin, a potential OCT2-antagonist, was administered 
i.v. 30 min prior to an ototoxic dose of cisplatin (8 mg/kg) and a possible re-
duction of the ototoxic side effect of cisplatin was then evaluated.
3.1 Laboratory animals (I-IV)
Sprague-Dawley rats (Scanbur AB, Sweden) were used for immunostaining 
studies in papers III and IV. In paper III, cultures of organs of Corti were iso-
lated from rat pups. Duncan-Hartley guinea pigs (BioJet, Uppsala, Sweden 
and Lidköpings Kaninfarm HB, Lidköping, Sweden) were used in all in vivo 
experiments in papers I-IV and for the immunostaining studies in papers I and 
IV. The animals were housed at the animal department of Karolinska Univer-
sity Hospital, Solna. All experimental animal studies in this thesis were per-
formed in accordance with the ethical standards at Karolinska Institutet and 
Stockholms Norra Djurförsöksetiska Nämnd, with ethical approval N423/04, 
N213/05 (paper I), N 372/08 (paper II), N32/07, N372/08, N320/09 (paper 
III) and N135/11 (paper IV). In paper IV, cochlea from one pig, (Sus scrofa) 
was used in the immunostaining experiment. The pig cochlea was harvested 
from the Department of Anesthesia, Uppsala University Hospital, and in ac-
cordance with the ethical standards at Uppsala University and Djurförsöks-
etiska Nämnd, with ethical approval C315/5 (paper IV).
3.2 Drugs (I-IV)
Cisplatin (I-IV)
In the in vivo studies (I-IV) and in the in vitro studies (I), cisplatin (Platinol® 
1 mg/ml, Bristol-Myers Squibb Pharmaceuticals, New York, USA) was used. 
In the in vitro studies (III), cisplatin (Cisplatin Mayne® 1 mg/ml, Hospira, 
LakeForest, USA) was administered.
Oxaliplatin (I and III)
For the in vivo studies (I and III) and in the in vitro studies (III) oxalipla-
tin (Eloxatin® 5 mg/ml, Sanofi-Aventis, Paris, France) was administered. For 
the in vitro studies (I) oxaliplatin (Oxaliplatin 5 mg/ml, Sigma-Aldrich 
Chemicals, Steinheim, Germany) was used. 
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Phenformin (IV)
For the in vivo studies, phenformin (phenformin hydrochloride 7.5 mg/ml, 
Sigma-Aldrich, Saint Louis, Mo, USA) was administered. 
3.3 Surgical procedures in vivo (I-IV)
In general the guinea pigs were anaesthetized with ketamine (Ketalar®) 
40 mg/kg and xylazine (Rompun®) 10 mg/kg i.m. for the electrophysiolo-
gical hearing tests and for surgery. In paper II a combination of fentanyl 
(Hypnorm®) and fluanisone (Midazolam®) were administered i.m. for an ade-
quate depth of anaesthesia. Atropine was given s.c. to reduce mucus in the 
airways. Lidocaine (Xylocaine®) was administered s.c. as local anaesthesia. 
During surgery the animals were placed on a heating pad and all surgical pro-
cedures were performed under clean conditions. The weight of each animal 
was checked daily and cisplatin or oxaliplatin treated animals were given a 
daily s.c. injection of 5 ml body warm saline. After the experiment the ani-
mals were deeply anaesthetized and euthanized with an overdose of sodium 
pentobarbital.
Catheter in jugular vein (I-IV)
After a skin incision in the anterior neck, the internal jugular vein was identi-
fied and catheterized. One catheter was used to deliver the drug and the other 
or to obtain blood samples [121, 125]. 
Dorsolateral surgical approach for access to the cochlear base (I and II)
The animal was lying on its belly, attached to a head holder. The bulla bone 
behind the ear was resected and the basal turn of the cochlea was exposed. 
The thin layer of mucosa on the bone was gently removed. A small hole was 
drilled in the basal turn of the cochlea for sampling ST perilymph [80, 181].
Ventrolateral surgical approach for access to the cochlear apex (II)
The animal was laid on its back, attached to a head holder. A transversal skin 
incision was made anteriorly in the neck and the animal was supplied with a 
tracheostomy to ease its ventilation. After blunt dissection medial to the man-
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dible, the digastric muscle was reduced. The bulla bone was opened, thereby 
exposing the apical part of the cochlea. 
Construction of a silicone cup (II)
For aspirating clear ST perilymph from the cochlear apex, a silicone cup was 
constructed [182] (Fig. 6). First the mucosa was removed from the apex bone 
and then a thin layer of glue was applied with a tiny stick. Several layers of 
silicone were applied to construct a “cup” over the cochlear apex. A sharp 
picker was used to make a small fenestra in the cochlear bone, and clear ST 
perilymph from the apex then slowly filled up the cup. 
Fig. 6. Construction of the silicone cup on the cochlear apex. 
Access to CSF (I and II)
In paper I the occipital bone was opened and dura mater was exposed. A small 
hole was made in the dura mater to get access to CSF from the subarachnoid 
space [80]. In paper II the skin was removed from the neck to prepare for a 
suboccipital approach to aspirate CSF from cisterna magna [183]. 
3.4 Sampling procedures in vivo (I and II)
Sampling of blood (I and II)
Blood was sampled by catheter from the internal jugular vein (opposite side 
from drug administration). To avoid blood clots, sodium heparin in sodium 
chloride was administered in each catheter. One blood sample (about 0.35 ml) 
was replaced with the same volume of sodium chloride. 
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Sampling of ST perilymph from the base of the cochlea (I and II)
In paper I a syringe was attached to a micromanipulator and the syringe tip 
was inserted into the drilled hole in the basal turn of the cochlea. One µl of 
clear ST perilymph was aspirated from the basal turn of the cochlea [80, 181]. 
In paper II capillary tubes were used to collect ST perilymph. One capil-
lary was used to aspirate 1 µl clear ST perilymph from the basal turn of the 
cochlea [182]. 
Sampling of ST perilymph from “the cup”, i.e. from the apex of the 
cochlea (II) 
Capillary tubes were used for sequential sampling (no. 1–10) of 1 µl ST peri-
lymph from the ”silicone cup” on the cochlear apex [182]. (Fig. 6)
Sampling of CSF (I and II)
In paper I a syringe attached to a micromanipulator was used to aspirate clear 
CSF from the subarachnoid space [80]. In paper II a sharp syringe was used 
for a suboccipital puncture, and CSF was aspirated from cistern magna [183].
3.5 Drug analysis (I and II)
Samples of blood, CSF and ST perilymph were immediately stored on dry 
ice. Blood samples were ultrafiltrated and all samples were stored at –80ºC 
until analysis. Liquid chromatography (LC) with post column derivatization 
with N,N-diethyldithiocarbamate in a microwave field was used to determine 
the concentration of cisplatin, oxaliplatin, and MHC [75, 176, 184]. This is 
a unique method that analyses the parent drug not bound to proteins and the-
reby correlates to the true level of the active drug. 
3.6 Auditory brainstem response (I, III and IV)
ABR was used to evaluate the electrophysiological hearing thresholds of the 
guinea pigs. The animals were anaesthetized and placed in a sound-proof box 
during the test [79, 185]. ABR threshold shifts were calculated as the dif-
ference between hearing thresholds obtained before vs. after drug treatment, 
expressed in dB [125]. Sound stimuli at different frequencies and sound le-
vels were exposed direct to animal’s external auditory canal. During ABR the 
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impulses from the hair cells to the auditory cortex are registered via electro-
des inserted subcutaneously on the scalp. Various signal waves are recorded, 
corresponding to different neuroanatomical regions of the nerve impulse (wa-
ves I-V). Electrophysiological hearing threshold was defined as the lowest dB 
where a reproducible response could be recorded, adjusted in 5 dB steps. In 
this work the hearing thresholds were measured at the frequencies 6.3, 12.5, 
and 20 kHz. 
3.7 Renal function (I)
Renal damage increases the concentration of creatinine and urea in blood. 
Blood samples from the guinea pigs were centrifuged and the serum promptly 
frozen. S-creatinine and S-urea were analysed with a spectrophotometric met-
hod at Karolinska University Hospital.
3.8 Surface preparations (I, III and IV)
Apoptotic studies and analyses of TrxR activity in organs of Corti cell 
cultures (III)
Organs of Corti (organ of Corti and spiral limbus) from rat cochlea of 2 or 3 
day-old rat pupwere dissected in phosphate-buffered saline (PBS) and cultu-
red in wells.
Analysis in vivo of TrxR activity in cochlear tissue (III)
After sacrificing each guinea pig, both temporal bones were immediately re-
moved and the organ of Corti and lateral walls were isolated from the cochlea. 
Tissues from both left and right cochleae from the same animal were pooled 
in lysis buffer. Samples were promptly frozen on dry ice and stored at –80°C. 
Counting loss of hair cells (I, III and IV)
The cochleae were prepared for morphological analysis of hair cell loss. Af-
ter decapitation, the guinea pig cochlea was immediately removed from the 
temporal bone. The perilymphatic space was perfused and fixed with para-
formaldehyde. The basilar membrane with the organ of Corti was exposed 
by removing the bone and surrounding tissue, and the remaining cells were 
labelled with phalloidin to visualize actin in the stereocilia of the hair cells.
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Analysis of platinum in cochlear and renal tissues (I and IV)
Guinea pig cochleae were immediately removed from the temporal bones. 
The entire basilar membrane, including the organ of Corti and stria vascula-
ris, was dissected and dried for analysis of platinum in tissue. In paper I, one 
kidney was also subjected to analysis.
Immunohistochemistry (I, III and IV)
For immunohistochemical studies, rat and guinea pig cochleae were imme-
diately removed from the temporal bone after sacrifice. The cochleae were 
perfused and fixed in paraformaldehyde, then decalcified and embedded in 
paraffin. In paper IV, one kidney from each animal was removed and one half 
of the kidney was fixated in paraformaldehyde and then embedded in paraf-
fin. The paraffin embedded cochlea and kidney tissue were sectioned 5 µm 
thick and mounted on microscopy slides. In paper IV the pig cochleae were 
prepared for cryosectioning, (embedded in Tissue-Tek (OCT Polysciences), 
rapidly frozen and sectioned at 8-10 µm) [186]. The frozen sections stored 
below –70°C prior to immunohistochemistry. 
3.9 Counting loss of hair cells (I, III and IV)
Missing inner and outer hair cells were counted “blinded” in a fluorescence 
microscope from apex to base of the cochlea. The criterion for hair cell loss 
was scar formation. The results were presented in cochleograms, plotting the 
percentage of missing hair cells. 
3.10 Platinum in cochlear and renal tissues (I and IV)
Platinum concentrations in cochlear tissue were determined by inductively 
coupled plasma mass spectrometry (ICP-MS by Analytica AB, now called 
ALS Scandinavia AB, Luleå, Sweden).
3.11 Immunohistochemistry (I, III and IV)
The paraffin sections of cochlea and kidney tissue were deparaffinized and 
the slides boiled for 10 min in an antigen unmasking solution (Vector Labo-
ratories, Burlingame, Cal., USA) to improve the binding of the antibody to 
its epitope. All sections were incubated with blocking serum (5% goat serum) 
for 30 min at room temperature to minimize background staining. The prima-
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ry antibody was excluded in the negative controls. The fluorescence signals 
were analysed in a light microscope (Zeiss axio scope; Carl Zeiss, Germany) 
and with a laser confocal microscope (Nikon TE2000, Nikon, Japan) [187].
TrxR (I and III)
In paper I, TrxR expression was investigated immunohistochemically in unt-
reated guinea pig cochleae. Rabbit anti-rat thioredoxin reductase 1 (TrxR1) 
polyclonal antibodies, diluted 1:100 and 1:1000 (Upstate, New York, USA) 
were used as primary antibodies. All sections were incubated overnight at 
4°C. Bound antibodies were visualized with indocarbocyanine, Cy3, (red co-
lour) conjugated goat anti-rabbit antibody, diluted 1:1000 (Jackson Immuno 
Research Laboratories Inc, WestGrove, Pa). The secondary antibodies were 
applied for 60 min at room temperature.
In paper III, TrxR expression was investigated in cochleae from untreated rat 
pup (P2-P3). Rabbit anti-rat thioredoxin reductase 1 (TrxR1) polyclonal anti-
bodies, diluted 1:1000 (Upstate Technology Laboratories, New York) were 
used as primary antibodies. Incubation with secondary antibody goat anti-
rabbit (VectaStain Elite ABC kit, Vector Laboratories, Burlingame) for 40 
min was followed by incubation with the ABC reagent and DAB-hydrogen 
peroxide solution according to VectaStain instructions.
OCT2 (IV)
In paper IV, OCT2 expression was investigated in cochleae from untreated 
rat, guinea pig and pig cochleae. Rat and guinea pig kidney was used as a 
positive control for OCT2 as reported in previous studies [188, 189]. Rabbit 
anti-rat organic cation transporter 2 (OCT2) polyclonal antibodies, diluted 
1:100 (Alpha Diagnostic International, San Antonio, Tex., USA) were used as 
primary antibodies. All sections were incubated overnight at 4°C. OCT2 anti-
bodies were visualized by means of indocarbocyanine, Cy3 (red colour) con-
jugated goat anti-rabbit antibody, diluted 1:200 (Jackson Immuno Research 
Laboratories Inc, West Grove, Pa). The secondary antibodies were applied for 
60 min at room temperature.
Parvalbumin (IV)
In paper IV, double staining with parvalbumin was performed to identify the 
hair cells [187, 190]. Guinea pig and pig cochleae were used. Mouse anti-
parvalbumin, diluted 1:250 (Chemicon International, Hants, England) was 
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used as primary antibodies. All sections were incubated overnight at 4°C. 
Parvalbumin antibodies were visualized by means of Alexa fluor 488 (green 
colour) conjugated goat anti-mouse antibody, diluted 1:400 (Invitrogen, 
Carlsbad, Cal., USA). The secondary antibodies were applied for 60 min at 
room temperature.
DAPI (I and IV) 
The cell nuclei were counterstained with DAPI 4´,6-diamidino-2-phenylin-
dole (blue colour). In paper I, DAPI (diluted 1:10 000) were administered for 
1 min and sections were then mounted. In paper IV all slides were mounted 
with Vecta Shield mounting medium with DAPI, (Vector Laboratories) and 
nuclei from all sections were then counterstained.
3.12 Cell culture experiments with human colon carci-
noma cells (I)
HCT116 human colon carcinoma cells were used in the cell culture experi-
ment. Twenty four hours after incubation with cisplatin or oxaliplatin they 
were analysed by flow cytometry for apoptosis with antibodies against cas-
pase-3 and against caspase-cleaved cytokeratin-18. Ca2+ chelator (BAPTA-
AM) was used to investigate the involvement of calcium in the apoptotic pat-
hway. The involvement of reactive oxygen species was investigated by using 
the superoxide anion scavenger Tiron [191]. Tiron was also administered to 
enucleated HCT116 human colon carcinoma cells (cytoblasts) and cisplatin-
induced apoptosis was studied. TrxR activity was measured in cell lysates of 
the colon carcinoma cells after exposition of cisplatin or oxaliplatin.
3.13 Organ of Corti cell cultures (III)
Organs of Corti from P2 or P3 rat cochleae were cultured in well plates and 
exposed for 24 hours to cisplatin or oxaliplatin. The organs were either used 
to estimate hair cell loss, or for assessing the enzyme activity of TrxR. 
3.14 Thioredoxin reductase activity assay (I and III)
Insulin assay with end-point Trx-dependent insulin reduction [66, 192] was 
used to measure the activity of TrxR. In paper III, TrxR activity was measured 
in rat organ of Corti cell cultures and from guinea pig cochlea in vivo (organ 
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of Corti and the lateral wall) [63]. In brief, cells were incubated with recom-
binant mutant human Trx and insulin, and the absorbance was measured with 
a VersaMax microplate reader (Molecular Devices Corporation, Sunnyvale, 




For additional information on the statistical calculations, please see the data 
analysis and statistics sections of each individual paper. The trapezoidal rule 
was used for the pharmacokinetic evaluations of the AUC studied in paper 
I. The variability of AUC was determined according to the principles given 
by Yuan [194]. A two-tailed nonparametric Mann–Whitney U-test was used 
to compare two independent groups. The wilcoxon rank test was used in the 
experiments with cultured tumour cells in paper I. Differences for which P-
values were 0.05 or less were considered to be statistically significant (papers 
I, II and IV). A two-way ANOVA was used to compare hair cell densities and, 
in paper III, one-way ANOVA for the TrxR activity in the in vitro studies. 
One-way ANOVA was also used in paper I, III and IV, when difference in 
hearing thresholds were calculated, using ABR. 
 
4. RESULTS 
4.1 Paper I: Cisplatin and oxaliplatin toxicity: importan-
ce of cochlear kinetics as a determinant for ototoxicity 
In vitro cell culture studies of apoptosis in HCT116 colon carcinoma cells 
treated with cisplatin or oxaliplatin 
Cisplatin-induced apoptosis of HCT116 colon carcinoma cells was reduced 
with a calcium chelator (BAPTA-AM) and by superoxide scavenging (Tiron), 
whereas oxaliplatin-induced apoptosis remained unaffected. These results are 
shown in Paper I (Fig. 1 B, C). Tiron also reduced apoptosis induced by cisp-
latin in enucleated HCT116 cells, shown in Paper I (Fig. 1 D).
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Table 1. Hair cells toxicity and total platinum concentration 96 hours after treatment 
with oxaliplatin or cisplatin 
ABR Hair cells Platinum
Oxaliplatin 16.6 mg/kg n=5 normal hearing no loss of hair cells 0.12 µg/kg
Cisplatin 12.5 mg/kg n=5 total deafness pronounced hair cell loss 0.63 µg/kg
Cisplatin 5 mg/kg n=5 normal hearing no loss of hair cells
In vitro cell culture studies on inhibition of TrxR by cisplatin and oxalipla-
tin in HCT116 colon carcinoma cells
The activity of TrxR was reduced more far after treatment with cisplatin than 
after oxaliplatin. The results are show in Paper I (Fig. 2).
In vivo studies on hair cell toxicity and total platinum concentration 96 
hours after treatment with oxaliplatin or cisplatin 
A high dose of cisplatin (12.5 mg/kg) caused a pronounced hair cell loss and 
total deafness. An equimolar i.v. dose of oxaliplatin (16.6 mg/kg) did not 
reveal any hair cells loss of and produced only minor changes in the hearing 
thresholds. The hair cell toxicity is presented in cochleograms in Paper I (Fig. 
4). In cochlear tissue, the total platinum concentrations were significantly lo-
wer after i.v. administration oxaliplatin (16.6 mg/kg) than after cisplatin (12.5 
mg/kg), 96 hours after drug treatment. The results are summarized in Table 1.
In vivo studies of the distribution of cisplatin and oxaliplatin in the cochlea
The AUC values in ST perilymph after i.v. administration of a high dose ox-
aliplatin (16.6 mg/kg) and a non-ototoxic low dose of cisplatin (5 mg/kg) 
were similar. AUC for cisplatin 12.5 mg/kg (recalculated from previous data) 
was significantly higher than AUC for an equimolar dose of oxaliplatin 16.6 
mg/kg. The AUC value, the maximal concentration and the half-life of the 
parent drug in ST perilymph are summarized in table 2 and the pharmacoki-
netics results are shown in Paper I (Figs. 5, 6 and 7).
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Immunohistochemical studies
In non-treated guinea pigs, immunoreactivity of TrxR was expressed in the 
organ of Corti (inner and outer hair cells), in the lateral wall (stria vascularis 
and fibrocytes of the spiral ligament), and in the neurons of spiral ganglion. 
The results are shown in Paper I (Fig. 3).
In summary
The Trx system appear to be involved in cisplatin-induced apoptosis in tu-
mour cells due to a reduced activity of TrxR. Positive immunoreactivity to 
TrxR in the cochlea indirectly supports the hypothesis that TrxR may be a tar-
get and might be involved in the ototoxic effect of cisplatin. A high concentra-
tion of cisplatin is present in ST perilymph, whereas the uptake of oxaliplatin 
is limited. This pharmacokinetic difference seems to be the main explanations 
for the more pronounced ototoxic side effect from cisplatin as compared to 
oxaliplatin. 
4.2 Paper II: Cochlear pharmacokinetics of cisplatin: 
An in vivo study in the guinea pig
In vivo pharmacokinetics 10–30 min after cisplatin administration 
The highest concentrations of cisplatin in blood-UF and ST perilymph samp-
led from the base of the cochlea were measured on the first sampling occa-
sion, i.e. 10 min after cisplatin administration. The concentration of cisplatin 
was significantly lower in CSF than in ST perilymph aspirated from the base 
of the cochlea at target times 10–30 min. The concentrations of cisplatin in 
the cochlear apex (mean of first sequential samples) were significantly lower 
Table 2. Pharmacokinetics of cisplatin and oxaliplatin in ST perilymph 
AUC C max T 1/2
Oxaliplatin 16.6 mg/kg n=13 238  µM 4.57 µM (15 min) 12 min
Cisplatin 5 mg/kg n=10 202 µM 2.95 µM (30 min) 33 min
Cisplatin 12.5 mg/kg n=21        515 µM (recalculated from previus data)
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in apex than in samples aspirated from the base of the cochlea at target times 
10 and 20 min. The concentration of cisplatin in apex increased significantly 
after only 20 min. No difference in cisplatin concentration in the cochlear 
base and apex could be observed at 30 min. These results are shown in Paper 
II (Fig. 1 and Table 1).
When cisplatin concentrations were calculated from capillaries 1-10, aspi-
rated from the cochlear apex, a significant difference in concentration was 
found between sample no. 1 and the mean of samples 4 and 5 at 10 min. This 
gradient was absent at 20 and 30 min. The last sequential samples, 8–10 sho-
wed an equivalent concentration of cisplatin, as in CSF at 10 and 20 minutes. 
The concentration of cisplatin in samples from cochlea base was compared 
with the mean level of cisplatin in sequential samples 4 and 5 aspirated from 
the cochlear apex and ST perilymph aspirated directly from the basal turn. A 
significant difference in concentration was observed at 10 and 20 min, but no 
difference was seen at 30 minutes. These results are shown in Paper II (Fig. 
2 and Table 1). 
In vivo pharmacokinetics 30–120 minutes after cisplatin administration
The elimination of cisplatin from ST perilymph aspirated from the base of 
the cochlea was delayed compared to the blood compartment. At 60 min, the 
levels of cisplatin in ST perilymph and blood-UF were equivalent. The pe-
rilymph–blood ratio then increased with time. The concentration of cisplatin 
in CSF was significantly lower than in ST perilymph at all target times. ST 
perilymph sampled from the basal turn of cochlea was analysed for MHC 
concentration. All samples had a concentration of MHC below the level of 
detection. The results are shown in Paper II (Figs. 3 and 4).
In summary
Ten minutes after i.v. administration, the concentration of cisplatin in ST pe-
rilymph was 4-fold higher in the basal turn of the cochlea compared with the 
apex. There seems to be an initially greater uptake of cisplatin in the basal 
part. Elimination of cisplatin from ST perilymph was delayed too.
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4.3 Paper III: Cisplatin and oxaliplatin are toxic to outer 
hair cells and both target thioredoxin reductase in 
organ of Corti cultures
In vitro studies on organ of Corti cell cultures 
Cisplatin and oxaliplatin both reduced the outer hair cell density in cultured 
organs of Corti. This effect was pronounced in the first half of the basal turn. 
The results are shown in Paper III (Fig. 1A, B). Exposure of rat organ of Corti 
cultures for 24 h to cisplatin, or oxaliplatin, reduced TrxR activity signifi-
cantly. In lateral wall extracts, TrxR activity decreased following exposure to 
cisplatin and oxaliplatin, respectively (Fig. 3A, B).
Immunohistochemical studies
Positive immunoreactivity to TrxR1 was identified in un-treated P2 rat 
cochlea. Immunoreactivity to TrxR1 was evident in stria vascularis, organ 
of Corti, and the spiral ganglion. Positive staining for the enzyme was seen 
in both inner and outer hair cells, as well as in parts of the developing spiral 
limbus. Stria vascularis exhibited intense staining. The results are shown in 
Paper III (Fig. 2).
Measuring TrxR activity in vivo
After i.v. administration of cisplatin and oxaliplatin to guinea pigs no reduc-
tion of the enzyme activity of TrxR in the organ of Corti could be verified 
after 24 hours. The results are shown in Paper III (Fig. 4).
In summary
Both cisplatin and oxaliplatin are toxic to outer hair cells when organs of 
Corti are directly exposed. TrxR becomes inhibited in parallel with signs of 
toxicity. TrxR may be a mediator of cisplatin ototoxicity, but in the in vivo 
study TrxR was unaffected.
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4.4 Paper IV: Immunohistochemical localization of OCT2 
in the cochlea of various species 
Immunohistochemical studies 
Strong immunoreactivity to OCT2 was localized in the SCs of organ of Corti 
and in type I SGCs. Similar immunolabelling for OCT2 was identified in rat, 
guinea pig, and domestic pig cochlea. Positive staining for OCT2 was seen 
in Deiters´ cells, Hensen´s cells, outer sulcus (Claudius´ ) and inner sulcus 
cells, outer and inner pillar cells and in the tympanic covering layer (TCL) 
localized under the basilar membrane. Type I SGCs displayed intense cyto-
plasmic OCT2 staining. Two-colour immunofluorescence technique was used 
on the guinea pig and pig cochlear slides to identify IHCs and OHCs. Positive 
cytoplasmic and nuclear immunoreactivity to parvalbumin was observed in 
IHCs with the connecting axons. Weak staining was also seen in the three 
OHC rows. Double staining with parvalbumin confirmed that no detected 
immunoreactivity to OCT2 was detected in the IHCs or in the three rows of 
OHCs. Type I SGCs showed both nuclear and cytoplasmic immunoreactivity 
to parvalbumin. The results are shown in Paper IV (Figs. 1 and 2).  
In vivo study with phenformin 
In general there was an obvious individual variability in the ototoxic side 
effect after cisplatin treatment in both groups. No differences in electrophy-
siological hearing threshold shifts were observed between the two groups at 
the three frequencies measured. Morphological evaluation revealed a pro-
nounced loss of OHCs whereas the IHCs were preserved in both groups. No 
difference in OHC loss was detected between the two groups. The content of 
platinum in cochlear tissue did not differ between the groups. The results are 
shown in Paper IV (Table 1).
In summary
OCT2 was localized in the SCs and in type I SGCs in cochleae from three 
animal species. The findings were verified with immunofluorescence double 
staining and analysed with confocal microscopy. In the in vivo study, phenfor-




Studies on animals are needed for inner ear research and the guinea pig is a 
well-established experimental model. The anatomy of the cochlea and hea-
ring in the guinea pig is in many ways similar to that humans but there are 
many differences between the guinea pig and the human ear [195, 196]. Why 
just cisplatin causes lesions in the inner ear is still not known, but animals 
used in this work have improved our knowledge of cisplatin-induced hearing 
loss. Due to the individual variability in ototoxic effects between animals 
large groups of animals are needed to achieve statistical significance. Howe-
ver, it is an ethical principle in experimental research to minimize the number 
of animals. 
5.2 DNA-independent apoptosis
Our results support previous studies that cisplatin increases the cell concen-
tration of ROS in cancer cells [197-199] and in cultured hair cells and [68, 
200-204], thereby exerting oxidative stress. Due to the differences in thera-
peutic effects and side effects of cisplatin and oxaliplatin, the difference in 
the DNA-independent mechanisms of apoptosis were studied [197]. Human 
colon cancer cells led to similar apoptosis following exposure to cisplatin and 
oxaliplatin, although via different pathways. The superoxide anion scavenger 
Tiron reduced apoptosis when treated with cisplatin, but not with oxaliplatin. 
These findings support the theory of involvement of ROS in the apoptotic ef-
fects of cisplatin. The calcium chelator BAPTA-AM reduced apoptosis when 
treated with cisplatin, whereas oxaliplatin-induced apoptosis was only mar-
ginally reduced. This finding also supports the theory that of the involvement 
of calcium in the apoptotic effects of cisplatin [6]. 
5.3 Thioredoxin system in the ear 
A reduced activity of TrxR following cisplatin treatment could in theory be 
due either to  a reduced amount of the enzyme subsequent to protein degra-
dation, or more likely as intracellular formation of inhibited TrxR protein 
species [61, 65]. Such inhibited TrxR activity diminishes the capacity of all 
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Trx-dependent antioxidant defence mechanisms, thereby inducing cell apo-
ptosis. In this work the enzyme activity of TrxR was measured both in vivo 
and in vitro.
In paper I reduced TrxR activity could be measured in cisplatin-induced apo-
tosis of colon carcinoma cells. In paper III it was demonstrated for the first 
time that cisplatin induced an inhibition of TrxR activity in the inner ear tissue, 
i.e. in organ of Corti culture. In the in vivo study, when cisplatin and oxalip-
latin were administered i.v., no detectable effect of the overall TrxR activity 
could be verified after 24 hours, thus leaving numerous questions unanswered 
regarding the role of the Trx system in cisplatin ototoxicity. Nevertheless, this 
finding does not exclude an effect of cisplatin on TrxR activity in vivo. There 
could be several reasons for the failure to demonstrate TrxR inhibition in the 
in vivo study. It is known that an ototoxic effect of cisplatin becomes evident 
96 hours after i.v. administration of cisplatin 8 mg/kg [79, 105]. 
In this study the activity of TrxR was evaluated after only 24 hours. One mig-
ht object that the time window for measuring TrxR activity was inappropriate. 
One obvious difference between the in vivo and the in vitro study of TrxR 
activity was the exposed concentration of cisplatin that might have affected 
the inhibition of TrxR. Data from paper II show that a maximum concentra-
tion of cisplatin in ST perilymph was 5.86 ± 1.43 µM and cisplatin could be 
measured up to 120 min after cisplatin (8 mg/kg) was administered i.v. In the 
in vitro study, organ of Corti cell cultures were exposed to 20 µM cisplatin 
for 24 hours. Positive immunohistochemical staining of TrxR in guinea pig 
cochlea (paper I) and in rat cochlea (paper III) supports the theory that cisp-
latin induced apoptosis of OHCs might involve an inhibition of TrxR activity, 
although it could not be demonstrated in vivo.
5.4 The importance of inner ear pharmacokinetics for 
cisplatin ototoxicity
Little has earlier been known about cisplatin transport to the hair cells or 
about the inner ear pharmacokinetics of cisplatin. With the present studies we 
have brought new insights into inner ear pharmacokinetics, showing that the 
passage of cisplatin across blood–perilymph barrier and the pharmacokine-
tics of cisplatin in the cochlea is important for the ototoxic effect of the drug. 
In vivo experiments are of importance for ototoxic studies, compared with 
studies based only on cell cultures when the inner ear barriers are circumven-
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ted. However, the concentration of cisplatin in ST perilymph may be only a 
rough estimate of the accessible drug concentration in the cochlea and there 
is no simple relationship between ST perilymph concentration and pharma-
cological effect expressed as a loss of OHCs. Laurell and co-workers (1995) 
showed that cisplatin could be measured in ST perilymph after i.v. injection 
of cisplatin (12.5 mg/kg). Ekborn and co-workers [79, 121, 125] performed 
pharmacokinetic studies on cisplatin and MHC in blood. 
In paper I it was shown that the lack of an ototoxic effect of oxaliplatin was 
due to a limited passage to ST perilymph. These findings were strongly sup-
ported by the results published in paper III showing that direct administration 
of oxaliplatin to the hair cells in vitro caused hair cell loss. In paper II it was 
demonstrated that the level of cisplatin in the cochlear base was more than 
4-fould than in the cochlear apex, 10 min after cisplatin administration. It can 
be speculated if the initially high concentration of cisplatin in the base might 
favor the toxic effect of cisplatin on OHCs, thereby inducing a longitudinal 
pattern of injury along the cochlear duct. Delayed elimination of cisplatin 
from ST perilymph compared from blood is shown in paper II. This finding 
suggested a prolonged exposure of the organ of Corti to cisplatin, which could 
be an important factor for the cytotoxic effect in the cochlea [80]. 
When perilymph is sampled from the base of the cochlea there is always a 
high risk of CSF contamination through the cochlear aqueduct. Salt et al. 
showed a contamination of approx. 15% CSF when 1 µl ST perilymph was 
aspirated from the basal turn of the cochlea [181, 205]. In our studies the con-
centrations of cisplatin in CSF were lower than in ST perilymph indicating 
that the estimated concentration of cisplatin could never be impossibly high. 
Cisplatin was also clearly shown to penetrate the blood–CSF barrier, due to 
the measurement of cisplatin in CSF in papers I and II [80].
In paper II a gradient of cisplatin concentration in ST could was establis-
hed due to the sequential sampling technique from the cochlear apex [182]. 
The fourth and fifth samples, of one µL, are regarded as representative of ST 
perilymph from the basal turn and the last samples, no. 8–10 to be highly 
contaminated with CSF [181, 205]. The results of this study support those 
above showing a concentration gradient in the cochlea with an initially higher 
concentration of cisplatin in the base compared to apex. At 10 min there was 
a significant difference in concentration between sample no. 1 and the mean 
of samples no. 4 and 5.
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Ekborn and co-workers (2003) showed that i.v. administration of MHC was 
more ototoxic than cisplatin [79]. In paper II, MHC was analysed in ST pe-
rilymph after i.v. cisplatin, but the concentration was below the limit of de-
tection [121, 125], not unexpected as the concentration of MHC in blood is 
only 8–9% of the total amount of cisplatin in blood [77, 121].  However, one 
cannot deny that MHC may be involved in the ototoxic effect in the inner ear 
fluids, as supported by the studies of Ekborn and co-workers (2003) [79].
The blood concentration of cisplatin is crucial for the inner ear pharmaco-
kinetics of cisplatin, as demonstrated by the results in papers I and II. A low 
variability of cisplatin in blood–UF was demonstrated and this is also known 
from previous studies in both experimental animals and in patients [4, 79, 
121, 125, 206]. When an i.v. low dose of cisplatin (5 mg/kg) was administe-
red the maximum concentration (2.95 µM) in ST perilymph was found after 
33 min. After an ototoxic dose of cisplatin (8 mg/kg) the maximum concen-
tration (5.86 µM) in ST perilymph was observed after only 10 min. Such dif-
ferences in peak time in ST perilymph were rather surprising, possibly show-
ing that the transport of cisplatin to the inner ear is not directly proportional 
to its concentration in blood.
5.5 Transport proteins and cisplatin ototoxicity
Drug transport is a widening scientific field of relevance for cisplatin cyto-
toxicity and its side effects. It has been demonstrated that profuse expression 
of Ctrl in the tumour is associated with a reduced antineoplastic effect of 
cisplatin in patients with ovarian cancer. This was attributed to an enhanced 
efflux of cisplatin from ovarian cancer cells which reduces the therapeutic 
response [207]. Due to similarities between the nephrotoxic and ototoxic ef-
fects of cisplatin, an active transport mechanism has been suggested for the 
inner ear and the kidney. Recent studies have demonstrated that OCT2 is 
involved in cisplatin-induced oto- and nephrotoxicity [39]. OCT2 is present 
in the cell membrane of the renal tubular cells and is known to be a specific 
transport protein for the uptake and accumulation of cisplatin, resulting in a 
nephrotoxic side effect [208, 209]. 
OCT2 was earlier immunohistochemically localized in the mouse cochlea 
[39, 168]. In cisplatin-treated OCT2 knockout mice, there were no signs of 
ototoxicity and only mild nephrotoxicity [39]. These studies were actually 
published after our immunohistochemical finding of the localization of OCT2 
in the cochlea. In paper IV, OCT2 was identified immunohisochemically in 
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the cochlea. Thanks to double staining with parvalbumin, OCT2 could be 
clearly localized in the SC of the organ of Corti and in the type I spiral SGCs.
These findings were surprising due to the assumed localization of OCT2 in 
stria vascularis, with active passage through the intrastrial fluid–blood barrier. 
Our findings support previous studies where cisplatin reportedly to induce 
toxic lesions in the SCs in the organ of Corti, mainly in Deiters´ cells [104, 
105]. Several ion channels [210] and gap junction proteins such as connexins 
are located in the SCs [187]. They are probably involved in the transport of 
potassium that is released by the hair cells and re-cycled to the endolymph 
compartment [103]. A reduced function of the SCs would probably induce 
secondary apoptosis of the hair cells [211]. The concentration of cisplatin in 
ST perilymph would therefore be of a considerable importance for these toxic 
effects but it is not known how cisplatin enters the OHCs [212, 213]. 
5.6 Blood–perilymph barrier and cisplatin ototoxicity
The finding that cisplatin can be measured in ST perilymph, at low concen-
trations after a low i.v. dose of  (5 mg/kg), demonstrates its ability to pene-
trate the blood–perilymph barrier [80] i.e. vessels in the spiral portion of the 
cochlea [144]. The concept of active transport through the blood–perilymph 
and the intrastrial fluid–blood barrier could not be documented. The findings 
in the present work more support a passive transport to the different inner ear 
compartment and an active uptake to the target cells for cisplatin ototoxicity, 
in the organ of Corti involving interaction between the SCs and OHCs.
5.7 Individual variability of ototoxicity
The pathophysiology behind the individual variability for cisplatin-induced 
hearing loss is not known and was not studied in this work but some parame-
ters elucidated can be surmised to be involved. One can speculate that there 
might be an individual variation in redox system activity in the cochlea due 
to variations in the GSH and Trx redox systems. This speculation might be 
supported by Oldenburg and co-workers’ findings (2007) showing a speci-
fic genotype of the enzyme glutathione S-transferase explaning differences 
in cisplatin-induced ototoxicity between individuals [214]. Another reason 
could for the individual susceptibility to the drug could be variations in active 
transport mechanisms for cisplatin to the target cells for ototoxic effect. There 
could also be an individual passage of cisplatin to ST perilymph, i.e. across 
the blood–perilymph barrier due to variations in the microvascular anatomy. 
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5.8 Apoptosis of OHCs in the base of the cochlea
It is well known is that the basal parts of the cochlea are most seriously af-
fected by cisplatin [122-124, 215, 216]. Why there is a difference in OHC loss 
along the length of the cochlea is not understood. According to the present 
results there is an early high distribution of cisplatin to the cochlear base 
that could initiate an increased cytotoxic activity in the vulnerable cells for 
hearing. There might also be a variation in apoptotic mechanisms along the 
cochlea [217, 218]. The GSH and Trx systems might be less active in the 
cochlear base [70]. There could also be a variation in specific cisplatin-trans-
port proteins along the cochlea [80, 206]. 
5.9 Protection from cisplatin ototoxicity
Although extensive research has been performed to protect hearing during 
cisplatin treatment, no clinical oto-protective therapy has yet succeeded. The 
best treatment would be to protect the hearing and the end organs without in-
terfering with the antitumour effect of cisplatin. Studies on cisplatin kinetics 
in vivo will help to shed light on possible ways to prevent ototoxicity. There 
are a few findings in this work that might well be of interest for the develop-
ment of a protective approach against the ototoxic side effects of cisplatin.
One theoretical approach for oto-protection would be to block any active 
transport mechanism of cisplatin to the sensory hearing cells, as was studied 
in paper IV. Phenoformin, an anti-diabetic drug of the biguanide class was 
administered as a competetiv antagonsist to cisplatin for the binding to OCT2 
[219, 220]. In clinic phenformin is withdrawn from the market due to its 
development of lactic acidosis. Phenformin was administered i.v. to guinea 
pig and the ototoxic effect of cisplatin was evaluated, no protection could 
be seen. Due to our immunohistological finding that OCT2 was localized in 
the deepest compartment of the inner ear, in the supporting cells, OCT2 can 
be hypothesized as being involved in a more direct uptake of cisplatin by 
the hair cells. In previous studies, cimetidine [39, 178, 179, 221] and copper 
sulphate [38, 168] were shown to prevent cisplatin-induced ototoxicity by in-
terfering with a proposed active transport mechanism. When transport inhibi-
tors or competitors are given systemically, they interact with the parent drug 
and local administration is therefore to be preferred [180]. Further studies 
are needed to evaluate the passage of cisplatin from blood to the fluid-filled 
compartments of the cochlea. 
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From the pharmacokinetic results one can point out that very low concen-
trations of cisplatin in ST perilymph are found when a non-ototoxic dose of 
cisplatin is administered i.v. A treatment that would reduce an elevated con-
centration of cisplatin in ST perilymph, and then primarily in the basal parts 
would thereby have a potential oto-protective effect. 
5.10 Limitations of the studies 
Due to our knowledge that the most apical parts of the hair cells are situated 
in SM endolymph, the concentration of cisplatin in this compartment would 
have been of interest to analyse as one part of the pharmacokinetic studies. To 
sample endolymph from SM is a complicated procedure that could not be per-
formed in our animal model. In paper III there were two different species in 
the in vitro and in vivo study, which may have affected the outcome. In paper 
IV it would have been of interest to assess the concentration of phenformin 
in ST perilymph. Most important of all, in the in vivo studies, larger study 
groups would have been an advantage due to the wide ototoxic variations 
after treatment with cisplatin. For ethical reasons, however, this would have 
been difficult to perform.
5.11 Clinical applications and future studies 
Apart from drug-induced hearing loss, loss of hearing in the high frequen-
cies also follows noise trauma and age-related hearing loss. The OHCs in 
the cochlear base seem to be the most sensitive, in general. If studies using 
ototoxic drugs can improve our knowledge of the apoptotic mechanisms of 
the OHCs, this might also have implications for age-related hearing loss and 
noise-induced hearing loss. Further study of a proposed active transport me-
chanism of cisplatin to the inner ear and more knowledge of the vascular 
microanatomy of the inner ear barriers are also of importance in the deve-
lopment of cisplatin oto-protection. The importance of TrxR as a molecular 
target in cisplatin ototoxicity calls for further study. The individual ototoxic 
effects of cisplatin also need to be better studied. Once again, conclusions 
from ototoxic studies based only on cell cultures when the inner ear barriers 
are circumvented may be a little value unless they are combined with experi-
ments using a reliable in vivo model. 
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6. CONCLUSIONS
The general conclusions of the work presented in this thesis can be summa-
rized as follows:
The in vivo pharmacokinetics studies showed an extent transport of cisplatin 
across the blood–perilymph barrier and only a limited passage of oxaliplatin 
to ST perilymph. These pharmacokinetic findings appear to form one of the 
main explanations for the differences in ototoxic side effects between cisp-
latin and oxaliplatin. The initial high concentration of cisplatin in the base of 
the cochlea and the delayed elimination of cisplatin from ST perilymph may 
correlate to the loss of OHCs in this region of the cochlea. Administration of 
phenformin did not provide any oto-protection.
The in vitro studies showed an equal loss of hair cells in organ of Corti cell 
cultures following direct exposure of cisplatin or oxaliplatin in the growth 
medium. This support the hypothesis that the blood–perilymph barrier is of 
fundamental importance for the ototoxic effects of cisplatin. The Trx redox 
system seems to be involved in cisplatin-induced ototoxicity. Activity of 
TrxR was reduced in relation to apoptosis of the hair cells after direct admi-
nistration of cisplatin to organ of Corti cultures. Cisplatin-induced apotosis in 
human colon carcinoma cells also reduced the activity of TrxR.
In the immunohistochemical studies, TrxR and OCT2 were identified in the 
cochlea. Positive immunoreactivity to TrxR in indirectly supports the hypo-
thesis that TrxR targeting, at least in part, contributes to cisplatin-induced 
apoptosis of the vulnerable cells of hearing. OCT2 was identified in SCs and 
type I SGCs, indicating that OCT2 is primarily not involved in the uptake of 
cisplatin from the systemic circulation, but rather from deeper compartments 
of the cochlea. 
54
7.  POPULÄRVETENSKAPLIG SAMMANFATTNING
Det platina-innehållande cytostatikapreparatet cisplatin har ototoxiska biverk-
ningar. Den irreversibla sensorineurala hörselnedsättningen resulterar ofta i 
att cisplatin exkluderas och därmed kan effekten av cytostatikabehandlingen 
påverkas. Det övergripade målet med avhandlingsarbetet var att få mer kun-
skap om cisplatin-orsakad hörselnedsättning. Cisplatins farmakokinetik har 
analyserats i innerörats vätska. DNA-oberoende mekanismer som kan vara 
involverade i cisplatins apototiska effekt på innerörats cellförband har stude-
rats. Med immunohistokemi har ett potentiellt transportprotein för cisplatin 
identifierats i innerörat. Resultaten från avhandlingens arbeten ger en ökad 
kunskap om mekanismer bakom cisplatin-orsakad hörselnedsättning. Detta 
kan bidra till en framtida utveckling av protektiva åtgärder i syfte att skydda 
cisplatin-behandlade patienter från att drabbas av hörselnedsättning. Nedan 
följer en sammanfattning av artiklarna I-IV i avhandlingsarbetet:
I: Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a 
determinant for ototoxicity. “En studie på cisplatins och oxaliplatins tox-
iska effekter och betydelsen av cisplatins farmakokinetik i koklean för dess 
ototoxicitet”.
Resultaten i artikel I visade att cisplatins farmakokinetik har betydelse för 
preparatets ototoxicitet. Höga nivåer cisplatin uppmättes i i scala tympani 
perilymfa efter att cisplatin administrerats i.v. till marsvin. Resultaten jämför-
des med data från motsvarande försök med oxaliplatin, som saknar ototoxisk 
biverkan. Endast låga halter oxaliplatin kunde analyseras i scala tympani pe-
rilymfa och detta skulle kunna förkara avsaknad av ototoxisk biverkan. Vid 
cisplatin-inducerad apoptos av odlade colon cancer celler kunde man påvisa 
en minskad aktivitet av enzymet thioredoxin reduktas. Positiv immunoreakti-
vitet för thioredoxin reduktas kunde identifieras i koklean hos marsvin. Dessa 
fynd talar för att thioredoxin systemet kan vara involverat i DNA-oberoende 
apoptos av innerörats hårceller. 
II: Cochlear pharmaockinetics of cisplatin – an in vivo study in the gui-
nea pig. “En in vivo studie av cisplatins farmakokinetik i koklean hos mar-
svin”. 
I artikel II har cisplatins farmakokinetik studerats i scala tympani perilymfa 
hos marsvin. Resultaten visar en initialt hög koncentration av cisplatin i scala 
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tympani perilymfa i kokleans bas 10 min efter i.v. administration av cisplatin 
till marsvin. 4 ggr högre koncentration uppmättes i kokleans bas jämfört med 
apex. Detta kan vara en del av orsaken varför det är hårceller i kokleans bas 
som i första hand skadas av cisplatin. Cisplatin hade även en långsammare 
elimination från perilymfan jämfört med från blodet.
 
III: Cisplatin and Oxaliplatin are toxic to cochlear outer hair cells and 
both target thioredoxin reductase in organ of Corti cultures. “En studie 
som visar att en direkt exponering av oxaliplatin till organ of Corti cell kultur 
är toxiskt för kokleans yttre hårceller och ger en minskad aktivitet av thiore-
doxin reduktas”.
Artikel III utvärderar den toxiska effekten på hårceller efter en direkt expo-
sition av cisplatin och oxaliplatin till odlingsmedlet i cellkultur från organ 
of Corti. Thioredoxin systemet har studerats i relation till DNA-oberoende 
apoptos av hårceller både in vivo och in vitro. Resultaten visar att cisplatin 
och oxaliplatin har likartad toxisk effekt på de yttre hårcellerna vid en di-
rekt exponering i organkultur och att thioredoxin systemet är involverat i de 
apoptotiska mekanismerna. Nivån av enzymet thioredoxin reduktas i innerör-
ats cellförband påverkas dock inte efter administrering av cisplatin och oxali-
platin in vivo. Resultaten stärker fynden från arbete I, det vill säga att trans-
porten av cisplatin till innerörat är av betydelse för dess ototoxicitet.
IV: Immunohistochemical localization of OCT2 in the cochlea of various 
species. ”En studie som med immunohistokemi lokaliserar OCT2 i koklean 
hos olika arter”.
Artikel IV undersöker förekomsten och lokalisationen i innerörat  av ett trans-
port protein, som kan vara involverat i cisplatins ototoxiska effekt. Positiv 
immunoreaktivitet för organisk katjontransportör 2 (OCT2) kunde identifie-
ras i det kortiska organets stödjeceller och i spriral ganglion celler hos mar-
svin, råtta och gris. Lokalisationen av OCT2 talar för att transportproteinet 
inte medverkar i transporten av cisplatin från blodbanan men indikerar att det 
kan vara delaktig i en transport via stödjecellerna till yttre hårcellerna. Phen-
formin administrerades i.v. som en blockerare till OCT2.  I aktuell dos gav 
inte phenformin något skydd mot cisplatin-utlöst ototoxicitet.
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